

July 21, 2020



Pat McCutcheon, CEO of MediPharm Labs to Present at the Avicanna Hosted Virtual Symposium Titled "Medical Cannabis 2.0" in Partnership with Medical Cannabis by Shoppers™

- This year's annual symposium coincides with the expected launch of Avicanna Inc's (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) RHO Phyto™ advanced medical cannabis products, [manufactured by MediPharm Labs](#).
- In the wake of COVID-19, a virtual format will be used that allows for a broader reach to global patients and the medical community.
- The symposium will present the evolution of medical cannabis including the Avicanna-led advancements, in collaboration with MediPharm Labs for R&D for novel cannabinoid delivery forms and formulations in addition to enhanced access for patients by Medical Cannabis by Shoppers.
- Leading experts in R&D and clinical development will discuss the potential therapeutic benefits of medical cannabis to address the importance of working with healthcare practitioners for safe and effective dosing.

BARRIE, Ontario, July 21, 2020 (GLOBE NEWSWIRE) -- **MediPharm Labs Corp.**, (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that Pat McCutcheon, CEO & Co-Founder of MediPharm Labs will be participating at the Avicanna Hosted Virtual Symposium Titled "[Medical Cannabis 2.0](#)" in Partnership with Medical Cannabis By Shoppers™.

Patients and health care practitioners globally can join the virtual symposium to learn more about the potential advantages of medical cannabis and the advancement of product offerings including [MediPharm Labs manufactured products](#) such as Avicanna's RHO Phyto™ product offerings. In addition, experts will discuss the pharmacology, safety, and dosing guidelines of medical cannabis for therapeutic conditions. This includes presentations on the efficacy of cannabinoids for chronic pain, anxiety, depression, and comorbidities as well as an overview of the patient pathway to Medical Cannabis by Shoppers.

The webcast presentation will begin at 10:00am Eastern Time, and Pat McCutcheon, CEO

of MediPharm Labs will be presenting on a panel at 12:50pm Eastern Time. Participants may view the full agenda and access the webcast using the following link: <https://www.avicanna.com/symposium/> or through the events section of MediPharm Labs Investor Relations website at <https://ir.medipharmlabs.com/ir-calendar>.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian extraction facility. MediPharm Labs Australia was established in 2017.

For further information, please contact:

Laura Lepore, VP, Investor Relations and Communications

Telephone: 416-913-7425 ext. 1525

Email: investors@medipharmlabs.com

Website: www.medipharmlabs.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news

release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.



Source: MediPharm Labs Corp.